DM002
- Generic Name
- DM002
A Study of DM002 in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Ovarian NeoplasmsProstatic NeoplasmsEndometrial NeoplasmsColorectal NeoplasmsSolid Carcinoma
- Interventions
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT06751329
- Locations
- 🇺🇸
The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
🇦🇺Cancer Care Wollongong, Wollongong, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath